UK MHRA Says Time For ‘Tough Decisions’ On Entry To Innovative Pathway

The UK regulator wants to revise the broad definition it applies to drugs entering its Innovative Licensing and Access Pathway so that the scheme resembles similar offerings by other regulators, such as the EMA’s PRIME and the US FDA’s Breakthrough Therapy Designation.